The Breast Cancer Research Program includes 29 faculty members from eight departments and two schools to form an integrated program that is dedicated to research on the prevention, diagnosis and treatment of breast cancer. The program is currently supported by $3,465,104 in NCI funding and $4,755,188 in other peer-reviewed funding. Program members have diverse interests including research into breast health communications, the pathology and biology of premalignant lesions, the development of intrinsic breast cancer subtype assays, translational research on endocrine therapy resistance in the context of cooperative group neoadjuvant endocrine therapy trials, the development of novel therapeutics that target both tumor cells and bone and the immune system cells. We are also very actively investigating novel imaging approaches for predicting response to hormonal therapy. In addition, the program is now collaborating with the Washington University Genome Sequencing Center in an effort to unravel the genetic changes associated with breast susceptibility, initiation, progression, relapse, and resistance. Program members are developing new breast cancer models in order to develop preclinical justifications for investigator initiated clinical trials in our developmental therapeutics programs. Classes of agent under development include phosphoinositol-3-kinase inhibitors, hedgehog inhibitors, check point homolog kinase (CHK1) inhibitors and Trop2 antibodies. The program consists of a number of basic, translational, and clinical investigators who meet weekly in a highly interactive scientific milieu. Large numbers of breast cancer patients are being treated on clinical protocols at Washington University with a number of Siteman Cancer Center cores are essential for the mission ofthe program, including the Clinical Trials Core, Imaging Response Assessment Team, Tissue Procurement Core, the Molecular and Genomic Analysis Core, the Biostatistics Core, the Bioinformatics Core, and the Proteomics Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA091842-13
Application #
8705877
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521
Copper, Tara Conway; Jeffe, Donna B; Ahmad, Fahd A et al. (2018) Emergency Information Forms for Children With Medical Complexity: A Qualitative Study. Pediatr Emerg Care :
Stephens, Calvin J; Kashentseva, Elena; Everett, William et al. (2018) Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9. Gene Ther 25:139-156
Liu, Ying; Colditz, Graham A; Rosner, Bernard A et al. (2018) Comparison of Performance Between a Short Categorized Lifestyle Exposure-based Colon Cancer Risk Prediction Tool and a Model Using Continuous Measures. Cancer Prev Res (Phila) 11:841-848
McGill, Bryan E; Barve, Ruteja A; Maloney, Susan E et al. (2018) Abnormal Microglia and Enhanced Inflammation-Related Gene Transcription in Mice with Conditional Deletion of Ctcf in Camk2a-Cre-Expressing Neurons. J Neurosci 38:200-219
Sharma, Piyush K; Dmitriev, Igor P; Kashentseva, Elena A et al. (2018) Development of an adenovirus vector vaccine platform for targeting dendritic cells. Cancer Gene Ther 25:27-38
Garbow, Joel R; Tsien, Christina I; Beeman, Scott C (2018) Preclinical MRI: Studies of the irradiated brain. J Magn Reson 292:73-81
Dodson, Elizabeth A; Hipp, J Aaron; Lee, Jung Ae et al. (2018) Does Availability of Worksite Supports for Physical Activity Differ by Industry and Occupation? Am J Health Promot 32:517-526
Bauerle, Kevin T; Hutson, Irina; Scheller, Erica L et al. (2018) Glucocorticoid Receptor Signaling Is Not Required for In Vivo Adipogenesis. Endocrinology 159:2050-2061
Guggisberg, Ann M; Frasse, Philip M; Jezewski, Andrew J et al. (2018) Suppression of Drug Resistance Reveals a Genetic Mechanism of Metabolic Plasticity in Malaria Parasites. MBio 9:

Showing the most recent 10 out of 1244 publications